Telisotuzumab Adizutecan (NCT07744126)

Name: Telisotuzumab Adizutecan trial for Head and Neck Squamous Cell Carcinoma (NCT07744126)
Uploaded: 2026-10-31T05:32:05.058Z
Duration: 1 min 16 s
Description: Telisotuzumab Adizutecan trial for Head and Neck Squamous Cell Carcinoma (NCT07744126). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07744126.

A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: a one-minute explainerNCT077441261 min

Telisotuzumab Adizutecan trial for Head and Neck Squamous Cell Carcinoma (NCT07744126). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with recurrent or metastatic head-and-neck squamous cancer unsuitable for curative local treatment. At least 25% of tumor cells must express c-Met. No prior systemic treatment for recurrent or metastatic disease is allowed.

The idea: compare two doses of telisotuzumab adizutecan plus pembrolizumab against pembrolizumab with platinum chemotherapy and fluorouracil. The investigational drug delivers a DNA-replication blocker to c-Met-bearing cells; pembrolizumab releases an immune brake. Researchers compare response, progression and safety.

This phase 2 study plans 150 patients. AbbVie sponsors two recruiting US locations.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.